GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer

Cancer Science

Volumn 103, Issue 5, 2012, Pages 913-920

  Miyake, Tomohiro ^a   Nakayama, Takahiro ^a   Naoi, Yasuto ^a   Yamamoto, Noriaki ^b   Otani, Yoko ^a   Kim, Seung J ^a   Shimazu, Kenzo ^a   Shimomura, Atsushi ^a   Maruyama, Naomi ^a   Tamaki, Yasuhiro ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY   (Japan)

^b SYSMEX CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; PACLITAXEL;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; DNA MICROARRAY; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DNA METHYLATION; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; FLUOROURACIL; GLUTATHIONE S-TRANSFERASE PI; HUMANS; NEOADJUVANT THERAPY; PACLITAXEL; PROMOTER REGIONS, GENETIC; RECEPTORS, ESTROGEN;

EID: 84862784568     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02231.x     Document Type: Article

References (37)

1. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-9.
2. Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-27.
3. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-81.
4. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist 2006; 11: 574-89.
5. Kaufmann M, von Minckwitz G, Bear HD et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007; 18: 1927-34.
6. Colleoni M, Viale G, Goldhirsch A. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. Breast 2009; 18(Suppl. 3): S137-40.
7. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23.
8. Goldstein NS, Decker D, Severson D et al. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 2007; 110: 1687-96.
9. Naoi Y, Kishi K, Tanei T et al. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. Cancer 2011; 117: 3682-90.
10. Ayers M, Symmans WF, Stec J et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004; 22: 2284-93.
11. Coles BF, Kadlubar FF. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? BioFactors 2003; 17: 115-30.
12. Laborde E. Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ 2010; 17: 1373-80.
13. Adler V, Yin Z, Fuchs SY et al. Regulation of JNK signaling by GSTp. EMBO J 1999; 18: 1321-34.
14. Satta T, Isobe K, Yamauchi M, Nakashima I, Takagi H. Expression of MDR1 and glutathione S transferase-pi genes and chemosensitivities in human gastrointestinal cancer. Cancer 1992; 69: 941-6.
15. Whelan RD, Waring CJ, Wolf CR, Hayes JD, Hosking LK, Hill BT. Over-expression of P-glycoprotein and glutathione S-transferase pi in MCF-7 cells selected for vincristine resistance in vitro. Int J Cancer 1992; 52: 241-6.
16. Su F, Hu X, Jia W, Gong C, Song E, Hamar P. Glutathion S transferase pi indicates chemotherapy resistance in breast cancer. J Surg Res 2003; 113: 102-8.
17. Arai T, Miyoshi Y, Kim SJ et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol 2008; 34: 734-8.
18. Peters WH, Roelofs HM, van Putten WL, Jansen JB, Klijn JG, Foekens JA. Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases. Br J Cancer 1993; 68: 86-92.
19. Schmidt M, Bachhuber A, Victor A et al. p53 expression and resistance against paclitaxel in patients with metastatic breast cancer. J Cancer Res Clin Oncol 2003; 129: 295-302.
20. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998; 58: 4515-8.
21. Holm K, Hegardt C, Staaf J et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 2010; 12: R36.
22. Tanei T, Morimoto K, Shimazu K et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009; 15: 4234-41.
23. Shimomura A, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Association of loss of BRCA1 expression with centrosome aberration in human breast cancer. J Cancer Res Clin Oncol 2009; 135: 421-30.
24. Morimoto K, Kim SJ, Tanei T et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 2009; 100: 1062-8.
25. Huang J, Tan PH, Thiyagarajan J, Bay BH. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol 2003; 16: 558-65.
26. Oshima K, Naoi Y, Kishi K et al. Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer. Cancer Lett 2011; 307: 149-57.
27. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-77.
28. Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y, Noguchi S. BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res Treat 2011; 129: 69-77.
29. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-7.
30. Barrett T, Edgar R. Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol 2006; 411: 352-69.
31. Gilbert L, Elwood LJ, Merino M et al. A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol 1993; 11: 49-58.
32. Hachey DL, Dawling S, Roodi N, Parl FF. Sequential action of phase I and II enzymes cytochrome p450 1B1 and glutathione S-transferase P1 in mammary estrogen metabolism. Cancer Res 2003; 63: 8492-9.
33. Dawling S, Hachey DL, Roodi N, Parl FF. In vitro model of mammary estrogen metabolism: structural and kinetic differences between catechol estrogens 2- and 4-hydroxyestradiol. Chem Res Toxicol 2004; 17: 1258-64.
34. Pratt MA, Tibbo E, Robertson SJ et al. The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. Oncogene 2009; 28: 2710-22.
35. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007; 7: 791-9.
36. Honeth G, Bendahl PO, Ringner M et al. The CD44 + /CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008; 10: R53.
37. Croker AK, Allan AL. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH(hi)CD44 (+) human breast cancer cells. Breast Cancer Res Treat 2011; doi: 10.1007/s10549-011-1692-y [Epub ahead of print].